Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CFO and co-CEO James Martin will deliver a company overview presentation on September 9, 2025 at 12:00 p.m. Eastern time.
The event will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. Martin will be available for one-on-one meetings with institutional investors and industry professionals throughout the conference. The presentation materials are accessible on the company's website.
Cocrystal Pharma (Nasdaq: COCP) ha confermato la sua partecipazione alla H.C. Wainwright 27ª Annual Global Investment Conference. Il CFO e co-amministratore delegato James Martin presenterà una panoramica aziendale il 9 settembre 2025 alle 12:00, ora orientale.
L'evento si terrà al Lotte New York Palace Hotel, con opzioni di partecipazione sia in presenza sia virtuale. Martin sarà disponibile per incontri individuali con investitori istituzionali e professionisti del settore durante tutta la conferenza. I materiali della presentazione sono disponibili sul sito web della società.
Cocrystal Pharma (Nasdaq: COCP) anunció su participación en la H.C. Wainwright 27ª Annual Global Investment Conference. El director financiero y co-CEO James Martin ofrecerá una presentación con una visión general de la empresa el 9 de septiembre de 2025 a las 12:00 p.m., hora del Este.
El evento se celebrará en el Lotte New York Palace Hotel y permitirá asistencia presencial y virtual. Martin estará disponible para reuniones uno a uno con inversores institucionales y profesionales del sector durante la conferencia. Los materiales de la presentación están accesibles en la página web de la compañía.
Cocrystal Pharma (Nasdaq: COCP)는 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참가할 예정이라고 발표했습니다. 최고재무책임자(CFO) 겸 공동 CEO 제임스 마틴이 2025년 9월 9일 동부 시간으로 오후 12:00에 회사 개요 발표를 진행합니다.
행사는 롯데 뉴욕 팰리스 호텔에서 열리며, 현장 참여와 온라인 참석 모두 가능합니다. 마틴은 컨퍼런스 기간 동안 기관 투자자 및 업계 관계자들과의 1:1 미팅에 응할 예정입니다. 발표 자료는 회사 웹사이트에서 확인할 수 있습니다.
Cocrystal Pharma (Nasdaq: COCP) a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. Le directeur financier et co‑PDG James Martin présentera un aperçu de la société le 9 septembre 2025 à 12h00, heure de l'Est.
L'événement se tiendra au Lotte New York Palace Hotel, avec des options de participation en personne et virtuelle. Martin sera disponible pour des réunions en tête‑à‑tête avec des investisseurs institutionnels et des professionnels du secteur tout au long de la conférence. Les documents de présentation sont accessibles sur le site web de la société.
Cocrystal Pharma (Nasdaq: COCP) gab bekannt, dass das Unternehmen an der H.C. Wainwright 27th Annual Global Investment Conference teilnimmt. CFO und Co-CEO James Martin wird am 9. September 2025 um 12:00 Uhr Eastern Time eine Unternehmensübersicht präsentieren.
Die Veranstaltung findet im Lotte New York Palace Hotel statt und bietet sowohl persönliche als auch virtuelle Teilnahmeoptionen. Martin steht während der Konferenz für Einzelgespräche mit institutionellen Investoren und Branchenfachleuten zur Verfügung. Die Präsentationsunterlagen sind auf der Website des Unternehmens abrufbar.
- None.
- None.
BOTHELL, Wash., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time.
Mr. Martin will be available throughout the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. The Cocrystal Pharma presentation is posted to the Company website here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that addresses significant unmet needs by developing innovative antiviral treatments for challenging diseases including influenza, viral gastroenteritis, COVID, and hepatitis. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Contact:
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
# # #
FAQ
When is Cocrystal Pharma (COCP) presenting at the H.C. Wainwright Conference?
Who will be presenting for Cocrystal Pharma at the H.C. Wainwright Conference?
Where can I access Cocrystal Pharma's (COCP) H.C. Wainwright presentation?
How can investors attend Cocrystal Pharma's presentation at the H.C. Wainwright Conference?
